Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The authors acknowledge the support of Helmholtz Alliance ICEMED, the Helmholtz Initiative on Personalized Medicine iMed, the Helmholtz crossprogram topic Metabolic Dysfunction, the Alexander von Humboldt Foundation, the German Research Foundation (DFG) (SFB1123) and the European Research Council (AdG HypoFlam no
However, it did not address weight loss medications
In April 2025, the company discontinued its main obesity candidate, danuglipron, due to safety concerns
Tirzepatide is a newer medication and is still being assessed for its long-term effects and potential additional benefits, such as cardiovascular outcomes
US$ 29.34
US$ 26.12
US$ 20.04
US$ 20.65
US$ 24.62
US$ 20.12
US$ 20.80
US$ 29.06
